Recently, the Category 1 innovative drug Rilertinib Mesylate Tablets (trade name: 圣瑞沙) of Nanjing Sanhome Pharmaceutical Limited Company is approved for marketing by China NMPA. This drug is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression during or after previous treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) and have been confirmed by testing to be positive for the EGFR T790M mutation.

Rilertinib is an EGFR kinase inhibitor. The marketing of this drug provides a new treatment option for NSCLC patients.